Search research articles
Contact Us
Filters
Showing results (91-100 of 587) with videos related to
Page
of 59
Sort By:
Annals of the New York Academy of Sciences
|
November 17, 1994
Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide
M B Youdim, L Lavie, P Riederer
Neurotoxicity Research
|
January 2, 2007
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder
C Mehler-Wex, P Riederer, M Gerlach
Neurology
|
December 1, 1996
Pharmacology of selegiline
M Gerlach, M B Youdim, P Riederer
Pharmacopsychiatry
|
July 1, 1995
Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia
W E Müller, E Mutschler, P Riederer
Clinical Neurology and Neurosurgery
|
January 1, 1979
Distinction between benign and malignant type of Parkinson's disease
W Birkmayer, P Riederer, B H Youdim
Advances in Neurology
|
January 1, 1990
The role of MAO in dopaminergic transmission
P Riederer, C Konradi, M B Youdim
Biochemical Society Transactions
|
February 1, 1979
2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]
G P Reynolds, P Riederer, M Sandler
Advances in Neurology
|
January 1, 1996
Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids
M Gerlach, P Riederer, M B Youdim
European Journal of Pharmacology
|
June 5, 1992
The molecular pharmacology of L-deprenyl
M Gerlach, P Riederer, M B Youdim
Journal of Neural Transmission
|
January 1, 1987
HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients
G Sperk, G P Reynolds, P Riederer
Page
of 59
Search research articles
Search
Showing results (91-100 of 587) with videos related to
Sort By:
Page
of 59
Annals of the New York Academy of Sciences
|
November 17, 1994
Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide
M B Youdim, L Lavie, P Riederer
Neurotoxicity Research
|
January 2, 2007
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder
C Mehler-Wex, P Riederer, M Gerlach
Neurology
|
December 1, 1996
Pharmacology of selegiline
M Gerlach, M B Youdim, P Riederer
Pharmacopsychiatry
|
July 1, 1995
Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia
W E Müller, E Mutschler, P Riederer
Clinical Neurology and Neurosurgery
|
January 1, 1979
Distinction between benign and malignant type of Parkinson's disease
W Birkmayer, P Riederer, B H Youdim
Advances in Neurology
|
January 1, 1990
The role of MAO in dopaminergic transmission
P Riederer, C Konradi, M B Youdim
Biochemical Society Transactions
|
February 1, 1979
2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]
G P Reynolds, P Riederer, M Sandler
Advances in Neurology
|
January 1, 1996
Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids
M Gerlach, P Riederer, M B Youdim
European Journal of Pharmacology
|
June 5, 1992
The molecular pharmacology of L-deprenyl
M Gerlach, P Riederer, M B Youdim
Journal of Neural Transmission
|
January 1, 1987
HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients
G Sperk, G P Reynolds, P Riederer
Page
of 59